Procept BioRobotics CEO Dr. Reza Zadno Retires

By Hao Liu • Friday, July 25 10:30 • Permanent Link

Procept Biorobotics (NASDAQ: PRCT) has announced the retirement of Dr. Reza Zadno as President, CEO, and Director, effective September 1, 2025. Larry L. Wood will succeed him, joining the company on September 2, 2025. Dr. Zadno has led the company through significant growth and commercial expansion since 2020. The company confirmed strong underlying business trends and pre-announced 2Q25 revenue of approximately $79.2 million, representing annual growth of 48%.

Under Dr. Zadno's leadership, the number of global Aquablation procedures grew from a few hundred to nearly one hundred thousand, raising over $600 million in capital to support continued growth. The company also significantly increased enterprise value and revolutionized the treatment landscape for patients suffering from benign prostatic hyperplasia (BPH) and the doctors who treat them.

Larry L. Wood, with over 40 years of experience in the medical technology industry, will take over as President and CEO. He has been serving as Corporate Vice President and Group President at Edwards Lifesciences since 2023. Procept Biorobotics' board of directors and members of its audit committee believe that Wood's strengths and vast experience in the medical technology industry are a great fit with the opportunities ahead for the company.

Procept Biorobotics also pre-announced second quarter 2025 revenue of approximately $79.2 million, marking significant annual growth. The company will report second-quarter 2025 earnings results after the market close on Wednesday, August 6, 2025.

Procept Biorobotics' mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. The company manufactures the Aquabeam® and Hydros robotic systems, with the latter being the only AI-powered, robotic technology that delivers Aquablation therapy.

The company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. The market has reacted to these announcements by moving the company's shares -2.36% to a price of $58.64. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.